Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity
Cisplatin-induced kidney injury (CIKI) is a major adverse effect of this widely used chemotherapy agent. Targeting key events involved in CIKI, such as inflammation, apoptosis, mitochondrial dysfunction and oxidative stress, holds potential for mitigating CIKI and improving patient outcomes. Herein,...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | Redox Biology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725002502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839646078137270272 |
|---|---|
| author | Yanyan Deng Leizhi Xu Zhengtao Jiang Lin Chen Guanghao Zhu Chuting Xu Xiayan Chu Lixin Wang Xiaoting Niu Ling Chen Zhangping Xiao Jing Hu Guangbo Ge |
| author_facet | Yanyan Deng Leizhi Xu Zhengtao Jiang Lin Chen Guanghao Zhu Chuting Xu Xiayan Chu Lixin Wang Xiaoting Niu Ling Chen Zhangping Xiao Jing Hu Guangbo Ge |
| author_sort | Yanyan Deng |
| collection | DOAJ |
| description | Cisplatin-induced kidney injury (CIKI) is a major adverse effect of this widely used chemotherapy agent. Targeting key events involved in CIKI, such as inflammation, apoptosis, mitochondrial dysfunction and oxidative stress, holds potential for mitigating CIKI and improving patient outcomes. Herein, we report a novel N-containing chalcone derivative as a cysteine-targeting covalent binder of Keap1, which effectively mitigate cisplatin (CDDP)-induced mitochondrial dysfunction (CIMD) and CIKI through activating Keap1-Nrf2-ARE signaling. Initially, a chalcone derivative (A6) was identified as a strong Nrf2 agonist through high-throughput luminescence screening of in-house compounds. After two rounds of structural optimization, we developed a novel N-containing chalcone derivative (C5), which exhibits enhanced Nrf2 agonist activity, favorable drug-like properties, and improved renal-targeting ability. Cellular and animal studies showed that C5 significantly ameliorated CIMD and CIKI in CDDP-induced nephrocytes and CIKI mice via activating the Keap1-Nrf2-ARE signaling pathway in both settings. Mechanistically, C5 covalently modified Keap1 on two critical functional cysteines in Keap1 (Cys288 in the IVR domain and Cys319 in the Kelch domain), synergistically amplifying Nrf2 activation. As an extremely potent Nrf2 agonist, C5 mitigated CIKI by orchestrating antioxidant defenses, boosting mitochondrial energetics, promoting mitochondrial biogenesis, restoring mitochondrial dynamics, and inhibiting subsequent apoptotic cascade activation. Furthermore, Nrf2 knockdown markedly attenuated the nephroprotective effects of C5 in CIKI mice, confirming the critical role of Keap1-Nrf2 signaling in its nephroprotective mechanism. Collectively, a novel N-containing chalcone derivative was developed as an efficacious and renal-targeting covalent binder of Keap1, offering a promising therapeutic candidate for combating CIKI. |
| format | Article |
| id | doaj-art-0e848b0d00ab4bd3ab20d0605edab1d1 |
| institution | Matheson Library |
| issn | 2213-2317 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj-art-0e848b0d00ab4bd3ab20d0605edab1d12025-07-01T04:09:15ZengElsevierRedox Biology2213-23172025-09-0185103737Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicityYanyan Deng0Leizhi Xu1Zhengtao Jiang2Lin Chen3Guanghao Zhu4Chuting Xu5Xiayan Chu6Lixin Wang7Xiaoting Niu8Ling Chen9Zhangping Xiao10Jing Hu11Guangbo Ge12State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, ChinaDepartment of Nephropathy, The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, ChinaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Chemistry, Imperial College London, London, W12 0BZ, UKDepartment of Nephropathy, The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China; Corresponding author.State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Corresponding author.Cisplatin-induced kidney injury (CIKI) is a major adverse effect of this widely used chemotherapy agent. Targeting key events involved in CIKI, such as inflammation, apoptosis, mitochondrial dysfunction and oxidative stress, holds potential for mitigating CIKI and improving patient outcomes. Herein, we report a novel N-containing chalcone derivative as a cysteine-targeting covalent binder of Keap1, which effectively mitigate cisplatin (CDDP)-induced mitochondrial dysfunction (CIMD) and CIKI through activating Keap1-Nrf2-ARE signaling. Initially, a chalcone derivative (A6) was identified as a strong Nrf2 agonist through high-throughput luminescence screening of in-house compounds. After two rounds of structural optimization, we developed a novel N-containing chalcone derivative (C5), which exhibits enhanced Nrf2 agonist activity, favorable drug-like properties, and improved renal-targeting ability. Cellular and animal studies showed that C5 significantly ameliorated CIMD and CIKI in CDDP-induced nephrocytes and CIKI mice via activating the Keap1-Nrf2-ARE signaling pathway in both settings. Mechanistically, C5 covalently modified Keap1 on two critical functional cysteines in Keap1 (Cys288 in the IVR domain and Cys319 in the Kelch domain), synergistically amplifying Nrf2 activation. As an extremely potent Nrf2 agonist, C5 mitigated CIKI by orchestrating antioxidant defenses, boosting mitochondrial energetics, promoting mitochondrial biogenesis, restoring mitochondrial dynamics, and inhibiting subsequent apoptotic cascade activation. Furthermore, Nrf2 knockdown markedly attenuated the nephroprotective effects of C5 in CIKI mice, confirming the critical role of Keap1-Nrf2 signaling in its nephroprotective mechanism. Collectively, a novel N-containing chalcone derivative was developed as an efficacious and renal-targeting covalent binder of Keap1, offering a promising therapeutic candidate for combating CIKI.http://www.sciencedirect.com/science/article/pii/S2213231725002502Cisplatin-induced kidney injury (CIKI)The Keap1-Nrf2 complexCovalent binderNephroprotective mechanismMitochondrial dysfunction |
| spellingShingle | Yanyan Deng Leizhi Xu Zhengtao Jiang Lin Chen Guanghao Zhu Chuting Xu Xiayan Chu Lixin Wang Xiaoting Niu Ling Chen Zhangping Xiao Jing Hu Guangbo Ge Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity Redox Biology Cisplatin-induced kidney injury (CIKI) The Keap1-Nrf2 complex Covalent binder Nephroprotective mechanism Mitochondrial dysfunction |
| title | Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity |
| title_full | Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity |
| title_fullStr | Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity |
| title_full_unstemmed | Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity |
| title_short | Discovery of a novel chalcone-derived covalent Keap1 binder for mitigating cisplatin-induced mitochondrial dysfunction and nephrotoxicity |
| title_sort | discovery of a novel chalcone derived covalent keap1 binder for mitigating cisplatin induced mitochondrial dysfunction and nephrotoxicity |
| topic | Cisplatin-induced kidney injury (CIKI) The Keap1-Nrf2 complex Covalent binder Nephroprotective mechanism Mitochondrial dysfunction |
| url | http://www.sciencedirect.com/science/article/pii/S2213231725002502 |
| work_keys_str_mv | AT yanyandeng discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT leizhixu discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT zhengtaojiang discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT linchen discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT guanghaozhu discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT chutingxu discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT xiayanchu discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT lixinwang discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT xiaotingniu discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT lingchen discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT zhangpingxiao discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT jinghu discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity AT guangboge discoveryofanovelchalconederivedcovalentkeap1binderformitigatingcisplatininducedmitochondrialdysfunctionandnephrotoxicity |